Optinose Announces Reporting Date for Fourth Quarter 2021 Financial Results
Conference Call and Webcast to be held March 8, 2021 at 8:00 a.m. Eastern Time
Company to Present at the Cowen 42nd Annual Health Care Conference on March 9, 2022
YARDLEY, Pa., March 04, 2022 (GLOBE NEWSWIRE) — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the fourth quarter 2021 and corporate updates, before market open on Tuesday, March 8, 2022.
Company to Host Conference Call
Members of the Company’s leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at 8:00 a.m. Eastern Time on Tuesday, March 8, 2022.
To participate on the conference call, please dial (866) 916-4761 from the U.S. or +1 (409) 216-6496 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until Tuesday, March 15, 2021 by dialing (855) 859-2056 from the U.S. or +1 (404) 537-3406 from outside the U.S. and entering conference ID #8283756. A simultaneous webcast of the call and presentation can be accessed by visiting the Investors section of Optinose’s website at www.optinose.com. In addition, a replay of the webcast will be available on the Company website for 60 days following the event.
Cowen 42nd Annual Health Care Conference
In addition, the Company announced that announced that Chief Executive Officer Peter Miller will present a company overview and business update at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022, at 2:10 p.m. Eastern Time.
To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of the webcast will be available for 60 days following the conclusion of the event.
About Optinose
Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.
Optinose Investor Contact
Jonathan Neely
jonathan.neely@optinose.com
267.521.0531
